Modification in the derivatives structures enhanced their binding affinity, suggesting potential features critical for therapeutic efficacy, These derivatives inhibit the NF-kB pathway, impairing leukemia progression (Fontana et al. 2022). Here, NFKB1 is linked to leukemia.